United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2020_register
executive
2020-06-17
article
Mylan Institutional LLC et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
Notices
D09002ee1c105a557
D09002ee1c105a5c7
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Food and Drug Administration
originator
org
United States Government Agency or Subagency
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on March 9, 2020. The document announced the withdrawal of approval (as of April 8, 2020) of 16 abbreviated new drug applications (ANDAs) from multiple applicants. The document indicated that FDA was withdrawing approval of the following four ANDAs after receiving a withdrawal request from Lupin Pharmaceuticals, Inc., 111 South Calvert St., Harborplace Tower, 21st Floor, Baltimore, MD 21202: ANDA 065488, Azithromycin Oral Suspension, Equivalent to (EQ) 100 milligrams (mg) base/5 milliliters (mL); EQ 200 mg base/5 mL; ANDA 078410, Topiramate Tablets, 25 mg, 50 mg, 100 mg, and 200 mg; ANDA 090441, Imipramine Hydrochloride Tablets, 10 mg, 25 mg, and 50 mg; and ANDA 200563, Ciprofloxacin Oral Suspension, 250 mg/5 mL and 500 mg/5 mL. Before FDA withdrew the approval of these ANDAs, Lupin Pharmaceuticals, Inc., informed FDA that it did not want the approval of the ANDAs withdrawn. Because Lupin Pharmaceuticals, Inc., timely requested that approval of these ANDAs not be withdrawn, the approval of ANDAs 065488, 078410, 090441, and 200563 is still in effect.
85 FR 36598
https://www.govinfo.gov/app/details/FR-2020-06-17/2020-13070
2020-13070
fr17jn20-62
4164-01-P
Docket No. FDA-2020-N-0601
https://www.govinfo.gov/app/details/FR-2020-06-17/2020-13070
https://www.govinfo.gov/content/pkg/FR-2020-06-17/html/2020-13070.htm
https://www.govinfo.gov/content/pkg/FR-2020-06-17/pdf/2020-13070.pdf
1 p.
36598
36598
85 FR 36598
Mylan Institutional LLC et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction; Federal Register Vol. 85, Issue
NOTICE
2020-13070
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2020-N-0601
4164-01-P
2020-13070
Notice; correction.
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on March 9, 2020. The document announced the withdrawal of approval (as of April 8, 2020) of 16 abbreviated new drug applications (ANDAs) from multiple applicants. The document indicated that FDA was withdrawing approval of the following four ANDAs after receiving a withdrawal request from Lupin Pharmaceuticals, Inc., 111 South Calvert St., Harborplace Tower, 21st Floor, Baltimore, MD 21202: ANDA 065488, Azithromycin Oral Suspension, Equivalent to (EQ) 100 milligrams (mg) base/5 milliliters (mL); EQ 200 mg base/5 mL; ANDA 078410, Topiramate Tablets, 25 mg, 50 mg, 100 mg, and 200 mg; ANDA 090441, Imipramine Hydrochloride Tablets, 10 mg, 25 mg, and 50 mg; and ANDA 200563, Ciprofloxacin Oral Suspension, 250 mg/5 mL and 500 mg/5 mL. Before FDA withdrew the approval of these ANDAs, Lupin Pharmaceuticals, Inc., informed FDA that it did not want the approval of the ANDAs withdrawn. Because Lupin Pharmaceuticals, Inc., timely requested that approval of these ANDAs not be withdrawn, the approval of ANDAs 065488, 078410, 090441, and 200563 is still in effect.
Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240- 402-6980, Martha.Nguyen@fda.hhs.gov.
Withdrawal of Approval of Abbreviated New Drug Applications; Correction:
Mylan Institutional LLC et al.,
Martha.Nguyen@fda.hhs.gov
Federal Register
Vol. 85, no. 117
Office of the Federal Register, National Archives and Records Administration
2020-06-17
continuing
daily
deposited
born digital
257 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2020-06-17
P0b002ee1a7313003
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr17jn20
https://www.govinfo.gov/app/details/FR-2020-06-17
https://www.govinfo.gov/content/pkg/FR-2020-06-17/pdf/FR-2020-06-17.pdf
https://www.govinfo.gov/content/pkg/FR-2020-06-17/xml/FR-2020-06-17.xml
fdlp
36467
36714
DGPO
2020-06-17
2023-09-27
FR-2020-06-17
machine generated
eng
FR
FR-2020-06-17
85
117